IP Library Granted Patent US 11,124,765
Granted Patent B2
US 11,124,765 · App. 16/138,724 · Granted Sep 21, 2021

Derivation of human microglia from pluripotent stem cells

Inventors: James A. Thomson (Madison, WI); Nicholas E. Propson (Houston, TX); Michael P. Schwartz (Madison, WI); Zhonggang Hou (Madison, WI); Gene I. Uenishi (Madison, WI); Igor I. Slukvin (Verona, WI); William L. Murphy (Waunakee, WI); Jue Zhang (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation
C12N5/0622C12N5/0645C12N5/0647C12N5/0697G01N33/5014G01N33/5058C12N5/0062C12N5/0068C12N5/0606C12N2500/25C12N2501/115C12N2501/15C12N2501/22C12N2501/999C12N2506/02C12N2506/45C12N2513/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,124,765
App. No.
16/138,724
Granted
Sep 21, 2021
Kind
B2
Abstract

The present invention relates to methods for deriving human hematopoietic progenitors, primitive macrophages, and microglial cells from human pluripotent stem cells. In particular, provided herein are highly efficient and reproducible methods of obtaining human primitive macrophages and microglia from human pluripotent stem cells, where the primitive macrophages and microglia can be suitable for clinically relevant therapeutic applications.

Claims (4)

1. A method of obtaining human hematopoietic precursor cells, comprising culturing human pluripotent stem cells under normoxic conditions for about 24 hours, wherein the pluripotent stem cells are cultured on a substrate that promotes cell adhesion and in a culture medium consisting essentially of L-ascorbic acid-2-phosphate magnesium, sodium selenium, transferrin, insulin, NaHCO 3 , fibroblast growth factor 2 (FGF2), transforming growth factor beta 1 (TGFβ1), and a Rho kinase (ROCK) inhibitor, whereby the cultured pluripotent stem cells differentiate into human hematopoietic precursor cells (HPCs) expressing CD45 with a portion co-expressing CD34.

2. The method of claim 1 , wherein the substrate that promotes cell adhesion comprises Tenascin-C.

3. The method of claim 2 , wherein the Tenascin-C is recombinant human Tenascin-C.

4. The method of claim 1 , wherein the ROCK inhibitor is selected from the group consisting of Y-27632 and Blebbistatin.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2021
From: PROPSON, NICHOLAS; THOMSON, JAMES; SCHWARTZ, MICHAEL; HOU, ZHONGGANG; UENISHI, GENE; SLUKVIN, IGOR; MURPHY, WILLIAM; ZHANG, JUE
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 057212/0338 →
CONFIRMATORY LICENSE Recorded Nov 18, 2020
From: UNIVERSITY OF WISCONSIN MADISON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 054459/0836 →
Continuity (3)
Division 14986224 · Dec 31, 2015
Provisional Application 62098824 · Dec 31, 2014
Related Publication 20190078054A1 · Mar 14, 2019
Cited By (1)
US 12,421,517